{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:31:57Z","timestamp":1768674717555,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.jsat.2005.06.002","type":"journal-article","created":{"date-parts":[[2005,9,24]],"date-time":"2005-09-24T07:10:06Z","timestamp":1127545806000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone"],"prefix":"10.1016","volume":"29","author":[{"given":"Diana L.","family":"Sylvestre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry J.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc N.","family":"Gourevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3 Suppl 1","key":"10.1016\/j.jsat.2005.06.002_bib1","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1002\/hep.510260711","article-title":"Epidemiology of hepatitis C","volume":"26","author":"Alter","year":"1997","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jsat.2005.06.002_bib2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/00042560-199802001-00003","article-title":"The importance of preventing hepatitis C virus infection among injection drug users in the United States","volume":"18","author":"Alter","year":"1998","journal-title":"Journal of Acquired Immune Deficiency Syndromes Human Retrovirology"},{"key":"10.1016\/j.jsat.2005.06.002_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","article-title":"Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy","volume":"160","author":"Capuron","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2005.06.002_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up","volume":"8","author":"Dalgard","year":"2002","journal-title":"European Addiction Research"},{"key":"10.1016\/j.jsat.2005.06.002_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","article-title":"Treatment of chronic hepatitis C in active drug users","volume":"345","author":"Davis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1016\/j.jsat.2005.06.002_bib7","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and treatment of hepatitis C in injection drug users","volume":"36","author":"Edlin","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000051384","article-title":"Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C","volume":"18","author":"Fontana","year":"2000","journal-title":"Digestive Diseases"},{"key":"10.1016\/j.jsat.2005.06.002_bib9","first-page":"157","article-title":"Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population","volume":"96","author":"Ho","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.jsat.2005.06.002_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/qjmed\/94.3.153","article-title":"Managing chronic hepatitis C acquired through intravenous drug use","volume":"94","author":"Jowett","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.jsat.2005.06.002_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0033-3182(99)71208-9","article-title":"Neuropsychiatric toxicity associated with cytokine therapies","volume":"40","author":"Lerner","year":"1999","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jsat.2005.06.002_bib12","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2005.06.002_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1016\/j.jsat.2005.06.002_bib14","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002\u2014June 10\u201312, 2002","volume":"36","author":"National Institutes of Health","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2005.06.002_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1440-1746.2000.02082.x","article-title":"Treatment of hepatitis C with interferon and ribavirin","volume":"15","author":"Pianko","year":"2000","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2005.06.002_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/scnp.2001.0060277","article-title":"The neuroimmunology of stress and depression","volume":"6","author":"Raison","year":"2001","journal-title":"Seminars in Clinical Neuropsychiatry"},{"key":"10.1016\/j.jsat.2005.06.002_bib19","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jsat.2005.06.002_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib21","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1016\/S0002-9343(99)00393-9","article-title":"The alcoholic patient with hepatitis C virus infection","volume":"107","author":"Schiff","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.jsat.2005.06.002_bib22","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.2000.18.11.2316","article-title":"Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions","volume":"18","author":"Trask","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jsat.2005.06.002_bib23","first-page":"165","article-title":"Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness","volume":"7","author":"Van Thiel","year":"1995","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.jsat.2005.06.002_bib24","first-page":"328","article-title":"Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease","volume":"45","author":"Van Thiel","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jsat.2005.06.002_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","article-title":"Hepatitis C, interferon alfa, and depression","volume":"31","author":"Zdilar","year":"2000","journal-title":"Hepatology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547205001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547205001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:28:17Z","timestamp":1760038097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547205001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0740547205001339"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2005.06.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2005.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}